MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, SLNCF made $422K in revenue. -$14,957K in net income. Net profit margin of -3544.31%.

Income Overview

Revenue
$422K
Net Income
-$14,957K
Net Profit Margin
-3544.31%
EPS
-$0.11
Unit: Thousand (K) dollars

Income Statement
2026-03-31
2025-12-31
2025-09-30
Revenue
422 82* 159
Cost of sales
11 23* 64
Gross profit
411 59* 95
Research and development costs
9,122 6,121* 20,544
General and administrative expenses
7,026 4,959* 5,795
Restructuring charges
-1,324* 0
Operating loss
-15,737 -12,345* -26,244
Foreign currency gain/(loss), net
-482 -14,269* 1,934
Other income, net
571 1,170* 770
Benefit from r&d credit
691 -286* 2,583
Loss before income tax expense
-14,957 -25,730* -20,957
Income tax expense
0 8* 1
Net loss
-14,957 -25,738 -20,958
Basic EPS
-0.11 -0.182 -0.15
Diluted EPS
-0.11 -0.182 -0.15
Basic Average Shares
141,702,578 141,687,556 141,701,848
Diluted Average Shares
141,702,578 141,687,556 141,701,848
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net loss-$14,957K Loss before incometax expense-$14,957K Benefit from r&d credit$691K Other income, net$571K Revenue$422K Operating loss-$15,737K Gross profit$411K Foreign currencygain/(loss), net-$482K Cost of sales$11K Research and developmentcosts$9,122K General andadministrative expenses$7,026K

Silence Therapeutics plc (SLNCF)

Silence Therapeutics plc (SLNCF)